X0609 4 2026-07-24 0 0001853921 Scribe Therapeutics, Inc. SCTX 0001701815 Aghazadeh Behzad false C/O AVORO CAPITAL ADVISORS LLC 110 GREENE STREET, SUITE 800 NEW YORK NY 10012 1 0 1 1 See Remarks 0001633313 Avoro Capital Advisors LLC false 110 GREENE STREET SUITE 800 NEW YORK NY 10012 1 0 1 1 See Remarks 0001879253 Avoro Ventures LLC false 110 GREENE STREET, SUITE 800 NEW YORK NY 10012 1 0 0 1 See Remarks 0 Common Stock, par value $0.0001 per share 2026-07-24 4 P 0 2333333 15.00 A 3030983 I See footnotes Common Stock, par value $0.0001 per share 2026-07-24 4 P 0 50000 22.31 A 3080983 I See footnotes Common Stock, par value $0.0001 per share 2026-07-28 4 P 0 7905 18.25 A 3088888 I See footnotes The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds"). The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2. Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund. The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2). The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer. Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer 2026-07-28 Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer Chief Compliance Officer 2026-07-28 /s/ Behzad Aghazadeh 2026-07-28